News

Dabigatran approved for VTE prevention and treatment


 

The novel oral anticoagulant dabigatran has been approved for treating and reducing the risk of recurrence of deep venous thrombosis and pulmonary embolism, based on the results of four phase III studies, the manufacturer announced on April 7.

Specifically, the approved indications are for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days, and to reduce the risk of recurrence of DVT and PE in patients who have been previously treated. The dose is administered twice a day.

This is the second approval for dabigatran, a direct thrombin inhibitor marketed as Pradaxa by Boehringer-Ingelheim Pharmaceuticals. It was initially approved in 2010 for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Approval was based on four international phase III studies, according to a statement issued by the company.

The studies are the RE-COVER and RE-COVER II trials and the RE-MEDY and RE-SONATE trials.

Dabigatran is approved with a medication guide, and the prescribing information includes a boxed warning about the increased risk of thrombotic events and spinal/epidural hematoma when it is prematurely discontinued.

The updated prescribing information is available here. Serious adverse events associated with dabigatran should be reported to the Food and Drug Administration’s MedWatch program at 800-332-1088 or www.fda.gov/medwatch.

emechcatie@frontlinemedcom.com

Recommended Reading

VIDEO: Device detects more atrial fibrillation, but when is intervention necessary?
MDedge Cardiology
Continuous AF monitors raise questions about when to intervene
MDedge Cardiology
AAN issues nonvalvular atrial fibrillation stroke prevention guideline
MDedge Cardiology
Post-LVAD acute kidney injury is predictor of all-cause mortality
MDedge Cardiology
Physician/patient communication on ICDs deemed problematic
MDedge Cardiology
Warfarin beneficial after acute atrial fib–associated MI in chronic kidney disease
MDedge Cardiology
Apixaban approved for preventing DVT and pulmonary embolism after hip/knee surgery
MDedge Cardiology
Novel anticoagulants get nod in new AF guidelines
MDedge Cardiology
Patients with LBBB get bigger long-term survival bang from CRT-D
MDedge Cardiology
Apixaban provides larger medical cost savings than other NOACs
MDedge Cardiology